In the FLYER trial, they assessed whether 4R-CHOP+2R was noninferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with a favourable prognosis. Here, DDIT3 is linked to B-cell non-Hodgkin lymphoma.